Teva Pharmaceutical Industries Ltd.

First Quarter 2023 Results

May 10, 2023

Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such differences include risks relating to:

• our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers;
delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to
develop and commercialize biopharmaceutical products; competition for our innovative medicines, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected results from investments in our
product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and
our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
• our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread
outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel;
manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges
associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are
subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for
suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
• compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of
opioid medications and any delay in our ability to obtain sufficient participation of plaintiffs for the nationwide settlement of our opioid-related litigation in the United States; scrutiny from competition and pricing
authorities around the world, including our ability to successfully defend against the U.S. Department of Justice (“DOJ”) criminal charges of Sherman Act violations; potential liability for Intellectual property right
infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws; environmental
risks and the impact of Environmental, Social and Governance (“ESG”) issues;
• other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including
the ongoing conflict between Russia and Ukraine; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax
benefits, or of a change in our business;
and other factors discussed in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and our Annual Report on Form 10-K for the year ended December 31, 2023 (“Annual Report”), including in
the sections captioned "Risk Factors" and “Forward-looking statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-
looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures as defined by SEC rules. Please see our press release reporting our financial results for the first quarter of 2023, as well as our Quarterly Report on
Form 10-Q for the quarter ended March 31, 2023, for a reconciliation of the non-GAAP financial measures to their nearest GAAP equivalents. Management believes that such non-GAAP financial measures provide
useful information to investors to facilitate their understanding of our business because the non-GAAP financial measures are used by Teva's management and board of directors, in conjunction with other
performance metrics, to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management; the company’s
annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. Investors should consider the non-GAAP financial measures
in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing forward looking guidance for GAAP reported financial measures
or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of
certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without
unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.

Some amounts in this presentation may not add up due to rounding. All percentages have been calculated using unrounded amounts.

|2|
 Richard Francis

President and Chief Executive Officer

|3|
 Impression After 120 Days as CEO

Strong commercial portfolio Promising innovative pipeline

AUSTEDO®, AJOVY®, UZEDYTM and Strong innovative pipeline with
upcoming biosimilars proven targets / MoAs

Solid core businesses Strong historical capabilities

Strong generation of cash to pay down debt "Can do" culture with an innovative mindset

Taking proactive measures to address short-term challenges

Reaffirming 2023 Non-GAAP Outlook
around COGS management

|4|
 Introducing our new strategic framework and key
priorities focusing on growth and innovation

Thursday, May 18 12:00 pm ET

Details on Teva’s IR website or via [email protected]

|5|
Q1 Revenues Performance
% In local currency, compared to Q1 2022

+12% Europe Generics AUSTEDO $170m

Successful new
+10%
product Significant growth
launches Revenues of in prescriptions

$3.7b
International
+4%
+9% Markets Generics AJOVY
$95m
Higher revenues
across markets
+35%

|6|
Strong Revenues Growth in Local Currency
$ millions

Total revenue growth of 4% in local currency

in local currency in local currency

1,766
1,737

1,184
1,156

492 492

Q1-22 Q1-23 Q1-22 Q1-23 Q1-22 Q1-23

North America Europe International Markets
Q1-22 as reported Q1-23 as reported Local currency effect

|7|
AUSTEDO Continues to Reach More Patients ®

Continued growth of AUSTEDO prescriptions

AUSTEDO quarterly TRx
60,000 57,123
U.S. Revenues
$170 million
50,000

40,000

Revenues Growth
30,000
+10%
20,000

10,000 TRx Growth

+28%
0

Source: IQVIA US NPA Audit

|8| Revenue and TRx data is compared to Q1 2022

AUSTEDO XR Approved in February 2023

Demonstrated efficacy*

Three once daily dosing options available

Patient sample titration pack available

Teva’s shared solutions program provides ongoing patient support

Now available in the U.S. for the treatment of TD and chorea for HD

* The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington’s disease were somnolence, diarrhea, dry
|9| mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis
and insomnia.
 AJOVY – Global Growth
Quarterly Global Net Sales

$95m Net global sales of $95 million in Q1 2023:

UP Q1’23
32%
North America
$72m
Q1’22 $49 million, +36%
24% U.S. market share

Europe
$36 million, +17%
30% market share

International Markets
$10 million, up 74%

2019 2020 2021 2022 Q1’23

North America Europe International Markets

| 10 |
UZEDY™ (risperidone) Now Approved
RAPID ABSORPTION
Achieves therapeutic levels in plasma within 6 to 24 hours of administration1,2

STREAMLINED INITIATION
~$4B
No loading dose or oral supplementation is required2

FLEXIBLE 1- AND 2-MONTH DOSING INTERVALS LAI 2022 Market size

Two dosing intervals and 8 dosing options2

SUBCUTANEOUS INJECTION
Administered as a single-dose, prefilled syringe with a short, 5/8-inch needle2

DEMONSTRATED EFFICACY and KNOWN SAFETY PROFILE

Significant reductions in the risk of relapse vs placebo2
Safety profile expected to be similar to that of corresponding oral risperidone doses*

References: 1. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 2. UZEDY™ (risperidone) extended-release injectable suspension Current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.
| 11 | * The most common adverse reactions with risperidone (≥5% and greater than placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach
discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. The most
common injection site reactions with UZEDY (≥5% and greater than placebo) were pruritus and nodule.
Generics: Strong Growth in Europe and International Markets
$ millions

in local currency in local currency

932
876

400
388

Q1-22 Q1-23 Q1-22 Q1-23

Europe International Markets

Q1-22 as reported Q1-23 as reported Local currency effect

| 12 |
 Teva Innovative Medicine Pipeline
By development stage – as of May 1, 2023
Under Regulatory
Preclinical Phase 1 Phase 2 Phase 3 Pre-Submission
Review

TEV-56278 TEV-53408 Anti-TL1-A Olanzapine LAI Digihaler® Digihaler®

Oncology Gastrointestinal (TEV-48574) Schizophrenia (beclomethasone (budesonide and
Ulcerative Colitis dipropionate HFA) formoterol fumarate
TEV-56279 Crohn's Disease (U.S.) dihydrate)2
ICS-SABA
Neuroscience TEV-562861 Asthma (EU)
(TEV-56248)
Multiple System Asthma Asthma & COPD
TEV-56288 Atrophy
Neuroscience

TEV-48438 TEV-56192
Schizophrenia Neuroscience
TEV-562871
Parkinson’s
Disease
TEV-46000
Neuroscience
TECHNOLOGY PLATFORMS Pipeline is current as of May 1, 2023
1) In collaboration with MODAG.
2) Digital component approved in UK by MHRA.
Novel Small Digital
Biologic Molecule Respiratory Teva innovative medicine pipeline by development stage,
excluding country / regional launches of products submitted
or under review in new markets.

| 13 |
 Teva Biosimilar Franchise
By development stage – as of May 1, 2023
Under Regulatory Commercial
Preclinical Phase 1 Phase 3 Under Regulatory
Pre-Submission
Preclinical Phase 3 Review Biosimilar Products1, 2
Review

TEV-56285 Biosimilar to Prolia® Biosimilar to

& Xgeva ® Humira®
TEV-54142 (denosumab) (adalimumab)
*
TEV-56191 Biosimilar to Xolair® Biosimilar to
(omalizumab) Stelara®
TEV-56261
TEV-56289
Biosimilar to Eylea®
(ustekinumab)
*
(aflibercept)
*
TEV-56284 * Biosimilar to
Simponi®
(golimumab) *

Pipeline is current as of May 1, 2023

* In collaboration with Alvotech for the U.S. market.

Teva biosimilar pipeline by development stage, excluding
country / regional launches of products submitted or under
review in new markets.

1. Truxima® and Herzuma® are in collaboration with Celltrion in the U.S. and Canada.
| 14 | 2. Ranivisio® is in collaboration with BioEq in the UK (marketed as ONGAVIA®), in the EU (to be marketed as RANIVISIO®) and was submitted in Canada
Promising Late-Stage Assets Poised to Support Growth

Olanzapine LAI Potential to be first long-acting olanzapine with a

('749) favorable safety profile

ICS/SABA ('248) De-risked1 ICS/SABA fixed-dose addressing market needs

Anti-TL1-A ('574) Potential to be best-in-class for proven TL1A mechanism in UC/CD

| 15 | LAI: Long-Acting Injectable, UC: Ulcerative Colitis, CD: Crohn's Disease, ICS: Inhaled Corticosteroids, SABA: Short-Acting Beta Agonist
1. De-risked referring to an increased probability of success in clinical trials
 Our 2022 ESG Progress Report Highlights

Progress toward ambitious targets Economic impact

24% 21 $44 billion

reduction in total scope 1 and 2 new regulatory submissions in savings from Teva’s
greenhouse gas emissions (vs. in low - and middle-income generic medicines
2019, ahead of schedule to meet countries (2025 target: 75)* across 21 countries
2025 target: 25%)*

5 ~100% $20 billion

access to medicines programs of active employees trained contributed
(2025 target: 8) on compliance policies to GDP
(achieved 2022 target: 99%+) across 24 countries

| 16 | * Tied to Teva’s sustainable financial instruments (e.g., sustainability-linked bonds and sustainability linked revolving credit facility)
 Eli Kalif

Executive Vice President, Chief Financial Officer

| 17 |
Q1 2023 Summary

$ millions, except EPS Q1 2023 Q1 2022 Q1 2023 Q1 2022

GAAP Non-GAAP
Revenues* 3,661 3,661 3,661 3,661
Operating income (loss) 2 (713) 785 1,013

Net income (loss) attributable to Teva (205) (955) 457 609

(0.18) (0.86) 0.40 0.55

Earnings (loss) per share ($)** 1,115 million 1,107 million 1,128 million 1,112 million
shares shares shares shares

* Revenues are presented on a GAAP basis

| 18 |
** Earnings per share based on a fully diluted basis
Non-GAAP Adjustments
$ millions Q1 2023 Comments
Amortization 165

Impairment of long-lived assets 188

mainly related to estimated provisions recorded in connection with certain
Legal settlements 233
litigation cases in the U.S.
Equity Compensation Plans 32

Accelerated depreciation 25

Restructuring 56

Financial Expenses 23

Contingent Consideration 20

Other 63

Non-controlling interests (40)

Corresponding tax effect (104)

Total adjustments 661

| 19 |
Q1 2023 Non-GAAP Summary

$ billions, except EPS Q1 2023 Q1 2022 Change

Revenues* 3.7 3.7 0%
1.8 2.0 (10%)
Gross profit
49.1% 54.2% (5.2%)
0.8 1.0 (23%)
Operating income
21.4% 27.7% (6.2%)
EBITDA 0.9 1.1 (21%)

Net income attributable to Teva 0.5 0.6 (25%)

0.40 0.55 (0.15)

EPS ($) 1,128 million 1,112 million
shares shares

Free cash flow** 0.04 0.12 (65%)

* Revenues are presented on a GAAP basis

** Free cash flow includes cash flow from operating activities, beneficial interest collected in exchange for securitized accounts receivables,
| 20 | proceeds from divestitures of businesses and other assets, net of cash used for capital investment.
Spend Base
$ millions
+229 (+9%)
+324 in local currency (+12%)

2,876
2,648

1,675 1,865
(63%) (65%)

COGS 1,025 * 1,013 *

OPEX * (39%) (35%)
Other Income
-52 (-2%) -2 (0%)
Q1 2022 Q1 2023
Revenues 3,661 3,661
GP% 54.2% 49.1%
OP% 27.7% 21.4%

| 21 | * OPEX include R&D, S&M and G&A expenses

Site Consolidation
Number of manufacturing sites

28

80

52 49

December 2017 May 2023 December 2023

Continued footprint optimization

additional 4 manufacturing sites announced to be divested/closed beyond 2023
| 22 |
Free Cash Flow by Quarters
$ millions 1,140

795
716 685
625

301

117
59
41

Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023

Free cash flow includes cash flow from operating activities, beneficial interest collected in exchange for securitized accounts receivables,
| 23 |
proceeds from divestitures of businesses and other assets, net of cash used for capital investment.
 Ongoing Debt Reduction
$ billions

Net Debt 20.7 20.0

19.0 18.4 18.5

4.8 4.8 4.7 4.6 4.4

EBITDA MAT

Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023

Net Debt / EBITDA MAT* 4.29 4.16 4.02 4.00 4.25

Leverage 69% 69% 69% 71% 71%

| 24 | *Teva's Net Debt/EBITDA MAT covenant ratio limits are 4.25x for Q1 2023 - Q3 2023 and 4.00x for Q4 2023
 Net Debt Development
$ billions
$35.0 $34.0
$33.0

$31.0

$29.0

$27.0

$25.0

$23.0

$21.0

$19.0
$18.5

$17.0
Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23

| 25 |
 Debt Maturity Profile

As of December 31, 2022 As of March 31, 2023

3.5
3.4 3.4

2.9 3.0

2.5

2.1 2.0 2.1

1.9 2.0 2.0
1.8
1.6 1.6 1.6

1.0 1.0 1.0

0.8 0.8

- -
2023 2024 2025 2026 2027 2028 2029 2030 2031 … 2036 … 2046 2023 2024 2025 2026 2027 2028 2029 2030 2031 … 2036 … 2046

USD EUR CHF New-USD New-EUR

* In March 2023, Teva repaid $646 million of its USD 1.25% senior notes at maturity
26
2023 Non-GAAP Outlook
$ billions, except EPS or as noted 2023 Outlook 2022 Actual

Revenues* $14.8 – $15.4 $14.9

COPAXONE ($m)* ~500 691

AUSTEDO ($m)* ~1,200 971

AJOVY ($m)* ~400 377

Operating Income 4.0 – 4.4 4.1

Adjusted EBITDA 4.5 – 4.9 4.6

Finance Expenses ($m) ~1,000 904

Tax Rate 14% – 17% 11.7%

2.25 – 2.55 2.52

Diluted EPS ($)
1,123 million shares 1,115 million shares

Free Cash Flow** 1.7 – 2.1 2.2

CAPEX* 0.5 0.5

Foreign Exchange Volatile swings in FX can negatively impact revenue and income

•* Revenues and CAPEX are presented on a GAAP basis

| 27 | •** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables
In Summary

Reaffirming our 2023 non-GAAP guidance

AUSTEDO and AJOVY continue to drive growth

AUSTEDO XR now available in the U.S.

UZEDY will commercially launch in the coming days in the U.S.

Strong performance in Europe and International Markets

Significant focus on cost discipline and working capital management

Looking forward to introducing our new strategic framework and key priorities next week

| 28 |
Q&A
| 29 |
Additional
Information
Quarterly GAAP Income Statement
Q1 2023 Q1 2022
$ millions, except EPS Q1 2023 Q1 2022 Change
Margins Margins
Revenues 3,661 3,661 0%
COGS 2,079 56.8% 1,921 52.5% 8%
1,582 1,740 (9%)
Gross profit
43.2% 47.5% (4.3%)
R&D 234 6.4% 225 6.2% 4%
S&M 546 14.9% 584 15.9% (6%)
G&A 296 8.1% 296 8.1% (0%)
Legal settlements and loss contingencies 233 6.4% 1,124 30.7% (79%)
Impairments, restructuring and others 274 7.5% 276 7.5% (1%)
Other income (2) (0.1%) (52) (1.4%) (96%)
2 (713) (100%)
Operating income (loss)
0.1% (19.5%) 19.6%
Financial expenses, net 260 7.1% 258 7.0% 1%
Tax (19) 7.5%* 2 (0.2%)* N/A
Minority and share in profit (34) (0.9%) (18) (0.5%) 89%
Net income (loss) attributable to Teva (205) (5.6%) (955) (26.1%) (79%)
# of shares (diluted, millions) 1,115 1,107
Earnings per share ($) (0.18) (0.86)

| 31 | * Represents tax rate

Q1 2023 Foreign Exchange Impact

$ millions Q1 2023 Q1 2022 Diff FX Effect Diff net FX

Revenues 3,661 3,661 0 (128) 128

Operating income (loss)

2 (713) 715 (32) 747
GAAP

Operating income
785 1,013 (228) (33) (196)
Non-GAAP

| 32 |
Net Revenue and Non-GAAP Profitability
$ millions
4,100
3,982
3,910 3,887 3,884
3,786
3,661 3,661
3,595

53.8% 53.3% 53.6% 56.1% 54.2% 54.4% 53.0% 54.2%

49.1%

27.1% 26.8% 30.4% 27.7% 26.9% 27.2% 29.1%

26.4%
21.4%

Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023

Net Revenues Non-GAAP Gross Profit Margin Non-GAAP Operating Margin

| 33 |
Revenues by Activity and Geographical Area
$ millions Q1-22 Q2-22 Q3-22 Q4-22 Q1-23
North America Segment 1,737 1,904 1,809 2,002 1,766
Generic products 899 1,026 806 818 824
AJOVY® 36 49 57 75 49
AUSTEDO® 154 204 260 344 170
BENDEKA®/TREANDA® 82 83 77 75 63
COPAXONE® 86 94 105 101 76
Anda 342 308 371 450 424
Other 139 139 133 138 160
Europe Segment 1,156 1,171 1,069 1,129 1,184
Generic products 876 873 803 914 932
AJOVY® 30 29 30 35 36
COPAXONE® 72 72 63 61 59
Respiratory 71 65 62 75 68
Other 107 131 111 43 89
International Markets Segment 492 454 475 482 492
Generic products 388 394 393 411 400
AJOVY® 6 10 6 13 10
COPAXONE® 10 9 9 7 12
Other 88 40 67 51 70
Other 275 257 241 272 219
Total Teva 3,661 3,786 3,595 3,884 3,661

| 34 |
Non-GAAP Profits and EPS
$ millions, EPS in $

1,248
1,130
1,077 1,019
1,034 1,042
1,013 977

785

854
754 791
699 651 651 658
609
0.77 0.68 0.71 457
0.63 0.59 0.59 0.55 0.59
0.40

Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023

Non-GAAP Net Income Non-GAAP Operating Income Non-GAAP EPS

| 35 |
Q1 2023 Non-GAAP Operating Income
$ millions

-$228m
(-23%)
-$196m Local currency
(-19%)
(70)
(36)
(65)
(58)

1,013
785

Q1-22 North America Europe International Markets Other Activities Q1-23

| 36 |
 Quarterly Non-GAAP Operating Income
$ millions
1,130
37 (3%)
1,013 1,019 93 (8%)
977
51 (5%) 55 (5%) 29 (3%)
95 (9%) 112 (11%)
179 (18%) 366 785
(32%)
389 114 (15%)
360
381 (38%) (37%)
(38%) 345
(44%)

633
481 477 (56%)
402 (47%) (49%)
(40%) 332
(42%)

-6 (-1%)
Q1-22 Q2-22 Q3-22 Q4-22 Q1-23
North America Europe International Markets Other Activities
Revenues: 3,661 3,786 3,595 3,884 3,661

| 37 | Numbers in brackets present a percentage of the total figure

Quarterly Adjusted EBITDA*
$ millions

1,240
1,135 1,134 1,089
899

Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023

| 38 | Please see our press release reporting our financial results for the first quarter of 2023 for a reconciliation of Adjusted EBITDA to its nearest GAAP equivalent
Q1 2023 Adjusted EBITDA to Free Cash Flow
$ millions
(858)
(95%)

(279)

(83)

899 (186)

(245)
2
78
(139)
(328) 323 41
(145)
Non-GAAP Interest Tax payments AR Inventory AP & Other Securitization Operating Securitization Asset sales, Free cash flow
EBITDA payments, net cash flow reclass net;
Capex gross

| 39 | Q1 securitization cash flow net impact -$5m

Consolidated Balance Sheet
$ billions Mar 31, 2023 Dec 31, 2022 Diff
Cash and Cash Equivalents 2.1 2.8 (0.7)
AR Trade 3.4 3.7 (0.3)
Pre-paid Expenses and Other Current Assets 1.8 1.7 0.1
Inventory 4.1 3.8 0.3
Fixed Assets 5.8 5.7 0.0
Intangible Assets 6.0 6.3 (0.3)
Goodwill 17.8 17.6 0.2
Other Long Term Assets 2.4 2.3 0.1
Total Assets 43.5 44.0 (0.5)
AP Trade 2.4 1.9 0.5
SR&A 3.3 3.8 (0.4)
AP Other 3.7 3.7 (0.0)
Total Debt (ST+LT) 20.7 21.2 (0.5)
Other Long Term liabilities 4.8 4.7 0.0
Minority 0.8 0.8 (0.0)
Teva Shareholders’ Equity 7.9 7.9 (0.0)
Total Liabilities & Equity 43.5 44.0 (0.5)

| 40 |
Q1 2023 Debt Movements
$ billions 2.5 2.5

21.2 0.6 0.2 20.7 2.1

18.5

Dec 31, Debt issued Debt Debt FX and Mar 31, Cash Mar 31,
2022 tendered repayment Other 2023 balance 2023
Gross Debt Gross Debt Net Debt

| 41 |